Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
Portfolio Pulse from
Calidi Biotherapeutics has announced promising preclinical results for its RTNova platform, which successfully delivers transient gene therapy to tumors. The platform has shown efficacy in killing over 60 different tumor cell lines.
March 10, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calidi Biotherapeutics announced successful preclinical results for its RTNova platform, which delivers gene therapy to tumors and shows efficacy in over 60 tumor cell lines.
The announcement of successful preclinical results for Calidi's RTNova platform is likely to positively impact CLDI's stock price in the short term. The platform's ability to deliver gene therapy to tumors and its efficacy in killing over 60 tumor cell lines is a significant development in the biotech field, potentially increasing investor interest and confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100